AT-787

N/A

Report date: 2022/12/16 20:00:37

NME

Base Information

Drug NameAT-787

Drug Alias NameAT-787

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsRNA-directed RNA polymerase inhibitorsNonstructural protein 5A inhibitors

TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseRNA-directed RNA polymeraseNonstructural protein 5A

Therapy Area/IndicationsHepatitis C, ChronicHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsYes Bemnifosbuvir AT-777

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAtea Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAtea Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A